ID   K562-Lucena 1
AC   CVCL_D162
SY   K562-Lucena; K562-LUCENA; Lucena 1; Lucena
DR   BCRJ; 0127
DR   ChEMBL-Cells; CHEMBL4630604
DR   ChEMBL-Targets; CHEMBL4630704
DR   PubChem_Cell_line; CVCL_D162
DR   Wikidata; Q54899396
RX   PubMed=11246270;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 29-06-23; Version: 22
//
RX   PubMed=11246270; DOI=10.1590/S0001-37652001000100007;
RA   Rumjanek V.M., Trindade G.S., Wagner-Souza K., Meletti-de-Oliveira M.C.,
RA   Marques-Santos L.F., Maia R.C., Capella M.A.M.;
RT   "Multidrug resistance in tumour cells: characterization of the
RT   multidrug resistant cell line K562-Lucena 1.";
RL   An. Acad. Bras. Cienc. 73:57-69(2001).
//